Headlines

Large multicentre rheumatoid arthritis DCE-MRI study published

17 February 2017
A new publication in European Radiology deomonstrates the sensitivity of DCE-MRI in distinguishing treatments in rheumatoid arthritis of the hand and wrist as early as 6 weeks after commencing treatment.
Read

Exosect scientist offers first look at sprayable formulation of systemic herbicide

16 February 2017
Winchester, UK – Exosect researcher, Kristi Thomas, provided representatives from the agricultural industry with a preliminary insight into an Entostat® enabled sprayable formulation of a systemic herbicide.
Read

Exosect's Chief Technology Officer addresses UK government on significance of microbial formulation project

7 February 2017
Winchester, UK – Today, Exosect’s Chief Technology Officer, Dr. Aoife Dillon, addressed UK government policy makers on the future direction of Crop Protection and the important role the Agricultural Technologies Strategy plays in growing the UK’s innovation and knowledge base in this sector.
Read

Fuel3D unveils super high-resolution desktop 3D scanner

5 January 2017
Fuel3D, a leading 3D capture and imaging innovator, today announced the details of a new compact 3D scanner. The Fuel3D Desktop Scanner is a high-speed imaging and measurement system, designed for capturing extremely high-resolution 3D data
Read

Fuel3D unveils super-fast 360-degree 3D scanner

5 January 2017
Fuel3D, a leading 3D capture and imaging innovator, today announced the details of a new 360-degree scanner. The Fuel3D 360 Scanner is a high-speed imaging and measurement system, designed for capturing highly detailed 360-degree 3D data.
Read

Peer reviewed study shows Entostat sprayable formulation optimises delivery of synthetic chemistry

4 January 2017
Winchester, UK – A study, just published demonstrates the ability of Exosect’s proprietary lean formulation technology, to optimise the delivery of synthetic chemistry in a sprayable format. This data adds to the growing number of novel formulations made possible by Exosect’s inert formulation platform, Entostat®, in both dry and wet formats.
Read

Oxford PV attracts a further £8.1m funding and three key strategic investors

6 December 2016
Importantly, the bulk of this investment has come from three new strategic investors who see the potential of the Company’s technology to revolutionise the global solar market and help create a new, low-carbon future.
Read

Oxford PV signs Joint Development Agreement with a major industrial partner

1 December 2016
The agreement will see the two companies working together to further develop Oxford PV’s perovskite-based solar technology – taking it from lab scale to manufacturing-ready status. Oxford PV holds the world’s largest patent portfolio for the use of perovskite in photovoltaic (PV) applications and its’ technology already demonstrates the efficiency and long-term stability needed to move towards commercialisation.This
Read